Pipeline

PROGRAM

INDICATIONS

DISCOVERY

PRE-CLINICAL

PHASE 1/2

PIVOTAL

CAR-T (Allogeneic)

T-ALL/LBL

Memory NK (Allogeneic)

AML

Solid Tumors

+ mAb

Solid Tumors

Engineered

AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia
LBL = Lymphoblastic Lymphoma
mAb = Monoclonal Antibody

  Co-development of Wugen products in China, Hong Kong, Taiwan, Macao, and Singapore

AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia
LBL = Lymphoblastic Lymphoma
mAb = Monoclonal Antibody

  Co-development of Wugen products in China, Hong Kong, Taiwan, Macao, and Singapore

Lead Programs

WU-NK-101

Super-Charged to attack cancer

WU-CART-007

Engineered to target T-cell cancers

Next in our story
Next in our story